In BRCA1/2-mutant breast, ovarian, and prostate cancers, PARP blockade combined with anti-PD-1/PD-L1 antibodies—such as durvalumab and pembrolizumab—has shown improved response rates and prolonged progression-free survival compared to monotherapy. This evidence concerns the gene PARP1 and Familial prostate cancer.